AVXS AveXis, Inc.

76.69
+4.14  (6%)
Previous Close 72.55
Open 73.17
Price To book 9.08
Market Cap 2.13B
Shares 27,794,000
Volume 463,478
Short Ratio 9.52
Av. Daily Volume 443,781

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17834487
  2. 8-K - Current report 17834402
  3. 8-K - Current report 17780073
  4. 8-K - Current report 17770335
  5. DEF 14A - Other definitive proxy statements 17770303

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Initiate pivotal trial in 2Q 2017 pending a successful outcome of its FDA Type B CMC meeting. Update to be provided following receipt of minutes in early June 2017.
AVXS-101
Spinal muscular atrophy (SMA) Type 1

Latest News

  1. What Falling Estimates & Price Mean for AveXis, Inc. (AVXS)
  2. AveXis reports 1Q loss
  3. AveXis Reports First Quarter 2017 Financial and Operating Results
  4. AveXis to Report First Quarter 2017 Financial and Operating Results
  5. High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids
  6. AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
  7. AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology
  8. Which Biotechs Are Buyable As Sector Recovers In 2017?
  9. Cytokinetics SMA Drug Did Well in Early Study
  10. Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
  11. AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
  12. AveXis Inc Stock Is Spiking Again Today -- Here's Why
  13. AveXis, Esperion and Amgen Among Biotech Movers
  14. AveXis Reports Positive Data for SMA Gene Therapy
  15. AveXis Offers Easily The Best Treatment Option For SMA Type-1 Patients
  16. Edited Transcript of AVXS earnings conference call or presentation 16-Mar-17 8:30pm GMT
  17. Futures Steady: 2 'A' Stocks Set To Soar, 1 Mule Ready To Kick
  18. After-hours buzz: ADBE, AVXS, GOOS & more
  19. AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results